Avances en los criterios diagnósticos para la enfermedad de Alzheimer

1 Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-746. Summary | Full Text | PDF(173KB) | PubMed
2 Jack CR, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 257-262. PubMed
3 McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944. PubMed
4 Varma AR, Snowden JS, Lloyd JJ, Talbot PR, Mann DM, Neary D. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry 1999; 66: 184-188. PubMed
5 Dubois B, Albert ML. Amnestic MCI or prodromal Alzheimer's disease?. Lancet Neurol 2004; 3: 246-248. Summary | Full Text | PDF(100KB) | PubMed
6 Lavenu I, Pasquier F, Lebert F, Pruvo JP, Petit H. Explicit memory in frontotemporal dementia: the role of medial temporal atrophy. Dement Geriatr Cogn Disord 1998; 9: 99-102. PubMed
7 Pillon B, Deweer B, Michon A, Malapani C, Agid Y, Dubois B. Are explicit memory disorders of progressive supranuclear palsy related to damage to striatofrontal circuits? Comparison with Alzheimer's, Parkinson's, and Huntington's diseases. Neurology 1994; 44: 1264-1270. PubMed
8 Fossati P, Harvey PO, Le Bastard G, Ergis AM, Jouvent R, Allilaire JF. Verbal memory performance of patients with a first depressive episode and patients with unipolar and bipolar recurrent depression. J Psychiatr Res 2004; 38: 137-144. PubMed
9 Petersen RC, Smith G, Kokmen E, Ivnik RJ, Tangalos EG. Memory function in normal aging. Neurology 1992; 42: 396-401. PubMed
10 Sarazin M, Chauvire V, Gerardin E, et al. The amnestic syndrome of hippocampal type in Alzheimer's disease: an MRI study. J Alzheimers Dis 2010; 22: 285-294. PubMed
11 Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010; 9: 1118-1127. Summary | Full Text | PDF(125KB) | PubMed
12 Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009; 66: 1469-1475. PubMed
13 Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006; 66: 1837-1844. PubMed
14 Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003; 62: 1087-1095. PubMed
15 Jicha GA, Abner EL, Schmitt FA, et al. Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiol Aging 2012; 33: 622e1. 622e16 PubMed
16 Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-292. PubMed
17 Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-279. PubMed
18 McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-269. PubMed
19 Prestia A, Caroli A, van der Flier WM, et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 2013; 80: 1048-1056. PubMed
20 Bouwman FH, Verwey NA, Klein M, et al. New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population. Dement Geriatr Cogn Disord 2010; 30: 1-7. PubMed
21 de Jager CA, Honey TE, Birks J, Wilcock GK. Retrospective evaluation of revised criteria for the diagnosis of Alzheimer's disease using a cohort with post-mortem diagnosis. Int J Geriatr Psychiatry 2010; 25: 988-997. PubMed
22 Galluzzi S, Geroldi C, Ghidoni R, et al. The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. J Neurol 2010; 257: 2004-2014. PubMed
23 Rami L, Sole-Padulles C, Fortea J, et al. Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD. Int J Geriatr Psychiatry 2012; 27: 127-134. PubMed
24 Frisoni G, Bocchetta M, Chételat G, et al. Imaging markers for Alzheimer's disease: which versus how. Neurology 2013; 81: 487-500. PubMed
25 Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367: 795-804. PubMed
26 Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 2012; 11: 1048-1056. Summary | Full Text | PDF(634KB) | PubMed
27 Fleisher AS, Chen K, Quiroz YT, et al. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol 2012; 11: 1057-1065. Summary | Full Text | PDF(965KB) | PubMed
28 Birrer RB, Vemuri SP. Depression in later life: a diagnostic and therapeutic challenge. Am Fam Physician 2004; 69: 2375-2382. PubMed
29 Bronnick K, Alves G, Aarsland D, Tysnes OB, Larsen JP. Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited. Neuropsychology 2011; 25: 114-124. PubMed
30 Hornberger M, Piguet O, Graham AJ, Nestor PJ, Hodges JR. How preserved is episodic memory in behavioral variant frontotemporal dementia?. Neurology 2010; 74: 472-479. PubMed
31 Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology 1988; 38: 900-903. PubMed
32 Tounsi H, Deweer B, Ergis AM, et al. Sensitivity to semantic cuing: an index of episodic memory dysfunction in early Alzheimer disease. Alzheimer Dis Assoc Disord 1999; 13: 38-46. PubMed
33 Sarazin M, Berr C, De Rotrou J, et al. Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study. Neurology 2007; 69: 1859-1867. PubMed
34 Derby CA, Burns LC, Wang C, et al. Screening for predementia AD: time-dependent operating characteristics of episodic memory tests. Neurology 2013; 80: 1307-1314. PubMed
35 Wagner M, Wolf S, Reischies FM, et al. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology 2012; 78: 379. 386 PubMed
36 Fortea J, Sala-Llonch R, Bartres-Faz D, et al. Cognitively preserved subjects with transitional cerebrospinal fluid β-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas. Biol Psychiatry 2011; 70: 183-190. PubMed
37 Swerdlow RH, Jicha GA. Alzheimer disease: can the exam predict the pathology?. Neurology 2012; 78: 374-375. PubMed
38 Dubois B, Touchon J, Portet F, Ousset PJ, Vellas B, Michel B. “The 5 words”: a simple and sensitive test for the diagnosis of Alzheimer's disease. Presse Med 2002; 31: 1696-1699. (in French). PubMed
39 Mura T, Proust-Lima C, Jacqmin-Gadda H, et al. Measuring cognitive change in subjects with prodromal Alzheimer's disease. J Neurol Neurosurg Psychiatry 2014; 85: 363-370. PubMed
40 Dierckx E, Engelborghs S, De Raedt R, et al. Verbal cued recall as a predictor of conversion to Alzheimer's disease in Mild Cognitive Impairment. Int J Geriatr Psychiatry 2009; 24: 1094-1100. PubMed
41 Ahmed S, Mitchell J, Arnold R, Nestor PJ, Hodges JR. Predicting rapid clinical progression in amnestic mild cognitive impairment. Dement Geriatr Cogn Disord 2008; 25: 170-177. PubMed
42 Estevez-Gonzalez A, Kulisevsky J, Boltes A, Otermin P, Garcia-Sanchez C. Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer's disease: comparison with mild cognitive impairment and normal aging. Int J Geriatr Psychiatry 2003; 18: 1021-1028. PubMed
43 Fowler KS, Saling MM, Conway EL, Semple JM, Louis WJ. Paired associate performance in the early detection of DAT. J Int Neuropsychol Soc 2002; 8: 58-71. PubMed
44 Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010; 75: 230-238. PubMed
45 Lowndes GJ, Saling MM, Ames D, Chiu E, Gonzalez LM, Savage GR. Recall and recognition of verbal paired associates in early Alzheimer's disease. J Int Neuropsychol Soc 2008; 14: 591-600. PubMed
46 Ricci M, Graef S, Blundo C, Miller LA. Using the Rey Auditory Verbal Learning Test (RAVLT) to differentiate Alzheimer's dementia and behavioural variant fronto-temporal dementia. Clin Neuropsychol 2012; 26: 926-941. PubMed
47 Siri S, Benaglio I, Frigerio A, Binetti G, Cappa SF. A brief neuropsychological assessment for the differential diagnosis between frontotemporal dementia and Alzheimer's disease. Eur J Neurol 2001; 8: 125-132. PubMed
48 Crane PK, Carle A, Gibbons LE, et al. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 2012; 6: 502-516. PubMed
49 Barbeau E, Didic M, Tramoni E, et al. Evaluation of visual recognition memory in MCI patients. Neurology 2004; 62: 1317-1322. PubMed
50 Guedj E, Barbeau EJ, Didic M, et al. Identification of subgroups in amnestic mild cognitive impairment. Neurology 2006; 67: 356-358. PubMed
51 Bird CM, Chan D, Hartley T, Pijnenburg YA, Rossor MN, Burgess N. Topographical short-term memory differentiates Alzheimer's disease from frontotemporal lobar degeneration. Hippocampus 2010; 20: 1154-1169. PubMed
52 Della Sala S, Parra MA, Fabi K, Luzzi S, Abrahams S. Short-term memory binding is impaired in AD but not in non-AD dementias. Neuropsychologia 2012; 50: 833-840. PubMed
53 Parra MA, Abrahams S, Logie RH, Mendez LG, Lopera F, Della Sala S. Visual short-term memory binding deficits in familial Alzheimer's disease. Brain 2010; 133: 2702-2713. PubMed
54 Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131-144. PubMed
55 Buerger K, Ewers M, Pirttila T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006; 129: 3035-3041. PubMed
56 Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem Int 2009; 55: 214-218. PubMed
57 Seppala TT, Nerg O, Koivisto AM, et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 2012; 78: 1568-1575. PubMed
58 Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003; 60: 652-656. PubMed
59 Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009; 66: 382-389. PubMed
60 Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 2011; 121: 597-609. PubMed
61 Le Bastard N, Martin JJ, Vanmechelen E, Vanderstichele H, De Deyn PP, Engelborghs S. Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiol Aging 2010; 31: 1867-1876. PubMed
62 Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-413. PubMed
63 Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2: 605-613. Summary | Full Text | PDF(284KB) | PubMed
64 Slaets S, Le Bastard N, Theuns J, et al. Amyloid pathology influences abeta1-42 cerebrospinal fluid levels in dementia with lewy bodies. J Alzheimers Dis 2013; 35: 137-146. PubMed
65 Perret-Liaudet A, Pelpel M, Tholance Y, et al. Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes. J Alzheimers Dis 2012; 31: 13-20. PubMed
66 Mattsson N, Andreasson U, Persson S, et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 2013; 9: 251-261. PubMed
67 Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64: 343-349. PubMed
68 Hampel H, Teipel SJ, Fuchsberger T, et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 2004; 9: 705-710. PubMed
69 Hulstaert F, Blennow K, Ivanoiu A, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999; 52: 1555-1562. PubMed
70 Ibach B, Binder H, Dragon M, et al. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiol Aging 2006; 27: 1202-1211. PubMed
71 Smach MA, Charfeddine B, Ben Othman L, et al. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease. Eur Neurol 2009; 62: 349-355. PubMed
72 Welge V, Fiege O, Lewczuk P, et al. Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm 2009; 116: 203-212. PubMed
73 Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234. Summary | Full Text | PDF(143KB) | PubMed
74 Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69: 98-106. PubMed
75 Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009; 8: 619-627. Summary | Full Text | PDF(180KB) | PubMed
76 Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302: 385-393. PubMed
77 van Rossum IA, Vos S, Handels R, Visser PJ. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J Alzheimers Dis 2010; 20: 881-891. PubMed
78 Ringman JM, Coppola G, Elashoff D, et al. Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease. Dement Geriatr Cogn Disord 2012; 33: 1-5. PubMed
79 Ringman JM, Younkin SG, Pratico D, et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008; 71: 85-92. PubMed
80 Bian H, Van Swieten JC, Leight S, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 2008; 70: 1827-1835. PubMed
81 de Souza LC, Lamari F, Belliard S, et al. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. J Neurol Neurosurg Psychiatry 2011; 82: 240-246. PubMed
82 Schoonenboom NS, Reesink FE, Verwey NA, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2012; 78: 47-54. PubMed
83 Brys M, Pirraglia E, Rich K, et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 2009; 30: 682-690. PubMed
84 Li G, Sokal I, Quinn JF, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 2007; 69: 631-639. PubMed
85 Snider BJ, Fagan AM, Roe C, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 2009; 66: 638-645. PubMed
86 Verwey NA, van der Flier WM, Blennow K, et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem 2009; 46: 235-240. PubMed
87 Fagan AM, Shaw LM, Xiong C, et al. Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol 2011; 68: 1137-1144. PubMed
88 Carrillo MC, Rowe CC, Szoeke C, et al. Research and standardization in Alzheimer's trials: reaching international consensus. Alzheimers Dement 2013; 9: 160-168. PubMed
89 Hort J, Bartos A, Pirttila T, Scheltens P. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur J Neurol 2010; 17: 90-96. PubMed
90 Mattsson N, Andreasson U, Persson S, et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 2011; 7: 386. 95 e6 PubMed
91 Joshi AD, Pontecorvo MJ, Clark CM, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med 2012; 53: 378-384. PubMed
92 Rowe CC, Pejoska S, Mulligan RS, et al. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. J Nucl Med 2013; 54: 880-886. PubMed
93 Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011; 305: 275-283. PubMed
94 Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131: 1630-1645. PubMed
95 Leinonen V, Rinne JO, Virtanen KA, et al. Positron emission tomography with [(18) F]flutemetamol and [(11) C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients. Eur J Neurol 2013; 20: 1043-1052. PubMed
96 Rinne JO, Wong DF, Wolk DA, et al. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid beta detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. Acta Neuropathol 2012; 124: 833-845. PubMed
97 Wolk D, Grachev I, Buckley C, et al. Association between in vivo fluorine 18—labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 2011; 68: 1398-1403. PubMed
98 Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29: 1456-1465. PubMed
99 Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-128. Summary | Full Text | PDF(394KB) | PubMed
100 Koivunen J, Scheinin N, Virta JR, et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 2011; 76: 1085-1090. PubMed
101 Visser PJ, Knopman DS. Amyloid imaging in the prediction of Alzheimer-type dementia in subjects with amnestic MCI. Neurology 2009; 73: 744-745. PubMed
102 Herholz K, Ebmeier K. Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol 2011; 10: 667-670. Summary | Full Text | PDF(72KB) | PubMed
103 Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65: 1509-1517. PubMed
104 Villemagne VL, Rowe CC. Amyloid imaging. Int Psychogeriatr 2011; 23: S41-S49. PubMed
105 Scholl M, Wall A, Thordardottir S, et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 2012; 79: 229-236. PubMed
106 Cairns NJ, Ikonomovic MD, Benzinger T, et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol 2009; 66: 1557-1562. PubMed
107 Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009; 73: 754-760. PubMed
108 Roe CM, Fagan AM, Grant EA, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7·5 years later. Neurology 2013; 80: 1784-1791. PubMed
109 Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59: 512-519. PubMed
110 Forsberg A, Almkvist O, Engler H, Wall A, Langstrom B, Nordberg A. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res 2010; 7: 56-66. PubMed
111 Grimmer T, Riemenschneider M, Forstl H, et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009; 65: 927-934. PubMed
112 Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009; 1: 371-380. PubMed
113 Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology 2009; 73: 1193-1199. PubMed
114 Tolboom N, van der Flier WM, Yaqub M, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med 2009; 50: 1464-1470. PubMed
115 Galton CJ, Patterson K, Xuereb JH, Hodges JR. Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 2000; 123: 484-498. PubMed
116 Lopez O, Litvan I, Catt KE, et al. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology 1999; 53: 1292-1299. PubMed
117 Snowden JS, Stopford CL, Julien CL, et al. Cognitive phenotypes in Alzheimer's disease and genetic risk. Cortex 2007; 43: 835-845. PubMed
118 Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 2011; 10: 785-796. Summary | Full Text | PDF(773KB) | PubMed
119 Crutch SJ, Lehmann M, Schott JM, Rabinovici GD, Rossor MN, Fox NC. Posterior cortical atrophy. Lancet Neurol 2012; 11: 170-178. Summary | Full Text | PDF(1250KB) | PubMed
120 Warren JD, Fletcher PD, Golden HL. The paradox of syndromic diversity in Alzheimer disease. Nat Rev Neurol 2012; 8: 451-464. PubMed
121 Ross SJ, Graham N, Stuart-Green L, et al. Progressive biparietal atrophy: an atypical presentation of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1996; 61: 388-395. PubMed
122 Henry ML, Gorno-Tempini ML. The logopenic variant of primary progressive aphasia. Curr Opin Neurol 2010; 23: 633-637. PubMed
123 Habek M, Hajnsek S, Zarkovic K, Chudy D, Mubrin Z. Frontal variant of Alzheimer's disease: clinico-CSF-pathological correlation. Can J Neurol Sci 2010; 37: 118-120. PubMed
124 Woodward M, Brodaty H, Boundy K, et al. Does executive impairment define a frontal variant of Alzheimer's disease?. Int Psychogeriatr 2010; 22: 1280-1290. PubMed
125 Woodward M, Jacova C, Black SE, et al. Differentiating the frontal variant of Alzheimer's disease. Int J Geriatr Psychiatry 2010; 25: 732-738. PubMed
126 Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer's disease. Brain 2007; 130: 2636-2645. PubMed
127 Johnson JK, Head E, Kim R, Starr A, Cotman CW. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol 1999; 56: 1233-1239. PubMed
128 Mendez MF, Joshi A, Tassniyom K, Teng E, Shapira JS. Clinicopathologic differences among patients with behavioral variant frontotemporal dementia. Neurology 2013; 80: 561-568. PubMed
129 Migliaccio R, Agosta F, Rascovsky K, et al. Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. Neurology 2009; 73: 1571-1578. PubMed
130 Snowden JS, Thompson JC, Stopford CL, et al. The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain 2011; 134: 2478-2492. PubMed
131 de Souza LC, Corlier F, Habert MO, et al. Similar amyloid-{beta} burden in posterior cortical atrophy and Alzheimer's disease. Brain 2011; 134: 2036-2043. PubMed
132 Leyton CE, Villemagne VL, Savage S, et al. Subtypes of progressive aphasia: application of the international consensus criteria and validation using {beta}-amyloid imaging. Brain 2011; 134: 3030-3043. PubMed
133 Rosenbloom MH, Alkalay A, Agarwal N, et al. Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology 2011; 76: 1789-1796. PubMed
134 Hof PR, Bouras C, Perl DP, Morrison JH. Quantitative neuropathologic analysis of Pick's disease cases: cortical distribution of Pick bodies and coexistence with Alzheimer's disease. Acta Neuropathol 1994; 87: 115-124. PubMed
135 Ball SL, Holland AJ, Watson PC, Huppert FA. Theoretical exploration of the neural bases of behavioural disinhibition, apathy and executive dysfunction in preclinical Alzheimer's disease in people with Down's syndrome: potential involvement of multiple frontal-subcortical neuronal circuits. J Intellect Disabil Res 2010; 54: 320-336. PubMed
136 Jellinger KA, Attems J. Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol 2010; 119: 421-433. PubMed
137 Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 2004; 62: 1148-1155. PubMed
138 Carotenuto A, Rea R, Colucci L, et al. Late and early onset dementia: what is the role of vascular factors? A retrospective study. J Neurol Sci 2012; 322: 170-175. PubMed
139 McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872. PubMed
140 McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007; 6: 305-313. Summary | Full Text | PDF(193KB) | PubMed
141 Jacova C, Peters KR, Beattie BL, et al. Cognitive impairment no dementia — neuropsychological and neuroimaging characterization of an amnestic subgroup. Dement Geriatr Cogn Disord 2008; 2: 238-247. PubMed
142 Johnson DK, Morris JC, Galvin JE. Verbal and visuospatial deficits in dementia with Lewy bodies. Neurology 2005; 65: 1232-1238. PubMed
143 Kraybill ML, Larson EB, Tsuang DW, et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 2005; 64: 2069-2073. PubMed
144 Kandiah N, Narasimhalu K, Lee J, Chen CL. Differences exist in the cognitive profile of mild Alzheimer's disease and subcortical ischemic vascular dementia. Dement Geriatr Cogn Disord 2009; 27: 399-403. PubMed
145 Moorhouse P, Song X, Rockwood K, et al. Executive dysfunction in vascular cognitive impairment in the consortium to investigate vascular impairment of cognition study. J Neurol Sci 2010; 288: 142-146. PubMed
146 Blennow K, Hampel H, Zetterberg H. Biomarkers in amyloid-beta immunotherapy trials in Alzheimer's disease. Neuropsychopharmacology 2014; 39: 189-201. PubMed
147 Pillai JA, Cummings JL. Clinical trials in predementia stages of Alzheimer disease. Med Clin North Am 2013; 97: 439-457. PubMed
148 Bateman RJ, Aisen PS, De Strooper B, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimer's Res Ther 2011; 3: 1. PubMed
149 Sperling RA, Jack CR, Aisen PS. Testing the right target and right drug at the right stage. Science Transl Med 2011; 3: 111cm33. PubMed
150 Rami L, Sala-Llonch R, Sole-Padulles C, et al. Distinct functional activity of the precuneus and posterior cingulate cortex during encoding in the preclinical stage of Alzheimer's disease. J Alzheimers Dis 2012; 31: 517-526. PubMed
151 Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41: 1088-1093. PubMed
152 Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41: 1094-1099. PubMed
153 Modrego PJ. Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. Curr Alzheimer Res 2006; 3: 161-170. PubMed
154 Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement; Accepted.
155 Gallassi R, Oppi F, Poda R, et al. Are subjective cognitive complaints a risk factor for dementia?. Neurol Sci 2010; 31: 327-336. PubMed
156 Amariglio RE, Becker JA, Carmasin J, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia 2012; 50: 2880-2886. PubMed
157 Mielke MM, Wiste HJ, Weigand SD, et al. Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology 2012; 79: 1570-1577. PubMed
158 La Joie R, Perrotin A, Barre L, et al. Region-specific hierarchy between atrophy, hypometabolism, and beta-amyloid (Abeta) load in Alzheimer's disease dementia. J Neurosci 2012; 32: 16265-16273. PubMed
159 Dickerson BC, Wolk DAAlzheimer's disease neuroimaging I. MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology 2012; 78: 84-90. PubMed
160 Magnin B, Mesrob L, Kinkingnehun S, et al. Support vector machine-based classification of Alzheimer's disease from whole-brain anatomical MRI. Neuroradiology 2009; 51: 73-83. PubMed
161 Buckner RL, Sepulcre J, Talukdar T, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci 2009; 29: 1860-1873. PubMed
162 Jagust W. Amyloid + activation = Alzheimer's?. Neuron 2009; 63: 141-143. PubMed
163 Fayed N, Davila J, Oliveros A, Castillo J, Medrano JJ. Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia. Acad Radiol 2008; 15: 1089-1098. PubMed
164 Kantarci K, Jack CR. Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin N Am 2003; 13: 197-209. PubMed
165 Qi Z, Wu X, Wang Z, et al. Impairment and compensation coexist in amnestic MCI default mode network. Neuroimage 2010; 50: 48-55. PubMed
166 Risacher SL, Saykin AJ, West JD, et al. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 2009; 6: 347-361. PubMed
167 Barkhof F, Polvikoski TM, van Straaten EC, et al. The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. Neurology 2007; 69: 1521-1527. PubMed
168 Fotuhi M, Do D, Jack C. Modifiable factors that alter the size of the hippocampus with ageing. Nat Rev Neurol 2012; 8: 189-202. PubMed
169 de Souza LC, Chupin M, Bertoux M, et al. Is hippocampal volume a good marker to differentiate Alzheimer's disease from frontotemporal dementia?. J Alzheimers Dis 2013; 36: 57-66. PubMed
170 Frisoni GB, Pievani M, Testa C, et al. The topography of grey matter involvement in early and late onset Alzheimer's disease. Brain 2007; 130: 720-730. PubMed
171 Whitwell JL, Dickson DW, Murray ME, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurol 2012; 11: 868-877. Summary | Full Text | PDF(2077KB) | PubMed
172 Giedd JN, Kozuch P, Kaysen D, et al. Reliability of cerebral measures in repeated examinations with magnetic resonance imaging. Psychiatry Res 1995; 61: 113-119. PubMed
173 den Heijer T, van der Lijn F, Koudstaal PJ, et al. A 10-year follow-up of hippocampal volume on magnetic resonance imaging in early dementia and cognitive decline. Brain 2010; 133: 1163-1172. PubMed
174 Lo RY, Hubbard AE, Shaw LM, et al. Longitudinal change of biomarkers in cognitive decline. Arch Neurol 2011; 68: 1257-1266. PubMed
175 Anchisi D, Borroni B, Franceschi M, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 2005; 62: 1728-1733. PubMed
176 Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003; 30: 1104-1113. PubMed
177 Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005; 32: 486-510. PubMed
178 Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 2002; 159: 738-745. PubMed
179 de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001; 98: 10966-10971. PubMed
180 Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: a006213. PubMed
181 Mosconi L, Mistur R, Switalski R, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging 2009; 36: 811-822. PubMed
182 Caroli A, Prestia A, Chen K, et al. Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J Nucl Med 2012; 53: 592-600. PubMed
183 Scholl M, Almkvist O, Bogdanovic N, et al. Time course of glucose metabolism in relation to cognitive performance and postmortem neuropathology in Met146Val PSEN1 mutation carriers. J Alzheimers Dis 2011; 24: 495-506. PubMed
184 Giovacchini G, Squitieri F, Esmaeilzadeh M, Milano A, Mansi L, Ciarmiello A. PET translates neurophysiology into images: A review to stimulate a network between neuroimaging and basic research. J Cell Physiol 2011; 226: 948-961. PubMed
185 Rocher AB, Chapon F, Blaizot X, Baron JC, Chavoix C. Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage 2003; 20: 1894-1898. PubMed
186 Bohnen NI, Djang DS, Herholz K, Anzai Y, Minoshima S. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J Nucl Med 2012; 53: 59-71. PubMed
187 Lehmann M, Ghosh PM, Madison C, et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain 2013; 136: 844-858. PubMed
188 Silverman DH, Truong CT, Kim SK, et al. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Mol Genet Metab 2003; 80: 350-355. PubMed
189 Kennedy AM, Frackowiak RS, Newman SK, et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett 1995; 186: 17-20. PubMed
190 Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 2004; 101: 284-289. PubMed
191 Small GW, Ercoli LM, Silverman DH, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2000; 97: 6037-6042. PubMed
192 Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007; 130: 2616-2635. PubMed
193 Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 2008; 49: 390-398. PubMed
194 Rabinovici GD, Jagust WJ, Furst AJ, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008; 64: 388-401. PubMed
195 Ewers M, Insel PS, Stern Y, Weiner MWAlzheimer's Disease Neuroimaging Initiative. Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease. Neurology 2013; 80: 1194-1201. PubMed
196 Garibotto V, Borroni B, Kalbe E, et al. Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence. Neurology 2008; 71: 1342-1349. PubMed
197 Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol 2012; 11: 1006-1012. Summary | Full Text | PDF(721KB) | PubMed
198 Isaac M, Vamvakas S, Abadie E, Jonsson B, Gispen C, Pani L. Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden — regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials. Eur Neuropsychopharmacol 2011; 21: 781-788. PubMed
199 Lowe VJ, Peller PJ, Weigand SD, et al. Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI. Neurology 2013; 80: 2130-2137. PubMed
200 Stricker NH, Chang YL, Fennema-Notestine C, et al. Distinct profiles of brain and cognitive changes in the very old with Alzheimer disease. Neurology 2011; 77: 713-721. PubMed
201 Butters MA, Lopez OL, Becker JT. Focal temporal lobe dysfunction in probable Alzheimer's disease predicts a slow rate of cognitive decline. Neurology 1996; 46: 687-692. PubMed
202 Cappa A, Calcagni ML, Villa G, et al. Brain perfusion abnormalities in Alzheimer's disease: comparison between patients with focal temporal lobe dysfunction and patients with diffuse cognitive impairment. J Neurol Neurosurg Psychiatry 2001; 70: 22-27. PubMed
203 Marra C, Villa G, Quaranta D, Valenza A, Vita MG, Gainotti G. Probable Alzheimer's disease patients presenting as “focal temporal lobe dysfunction” show a slow rate of cognitive decline. J Int Neuropsychol Soc 2012; 18: 144-150. PubMed
204 Mattsson N, Rosen E, Hansson O, et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 2012; 78: 468-476. PubMed
205 Savva GM, Wharton SB, Ince PG, et al. Age, neuropathology, and dementia. N Engl J Med 2009; 360: 2302-2309. PubMed
206 Holland D, Desikan RS, Dale AM, McEvoy LKAlzheimer's Disease Neuroimaging Initiative. Rates of decline in Alzheimer disease decrease with age. PLoS One 2012; 7: e42325. PubMed
207 Dartigues JF, Feart C. Risk factors for Alzheimer disease: aging beyond age?. Neurology 2011; 77: 206-207. PubMed
208 Chiu HF, Lam LC. Relevance of outcome measures in different cultural groups--does one size fit all?. Int Psychogeriatr 2007; 19: 457-466. PubMed
209 Caramelli P, Barbosa MT, Sakurai E, et al. The Pieta study: epidemiological investigation on successful brain aging in Caete (MG), Brazil. Methods and baseline cohort characteristics. Arq Neuropsiquiatr 2011; 69: 579-584. PubMed
210 Karlawish J. Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. Neurology 2011; 77: 1487-1493. PubMed
211 Antoine P, Pasquier F. Emotional and psychological implications of early AD diagnosis. Med Clin North Am 2013; 97: 459-475. PubMed
a Centre des Maladies Cognitives et Comportementales, INSERM U 1127, Institut du Cerveau et de la Moelle épinière, Paris, France
b Université Pierre et Marie Curie-Paris 6, AP-HP, Hôpital de la Salpêtrière, Paris, France
c Division of Neurology, University of British Columbia and Vancouver Coastal Health, Vancouver, BC, Canada
d UBC Division of Neurology, S152 UBC Hospital, BC, Canada
e Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, IDIBAPS Hospital Clinici Universitari, Barcelona, Spain
f BarcelonaBeta Brain Research Centre, Fundació Pasqual Maragall, Barcelona, Spain
g Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Mölndal, Sweden
h Department of Neurology, University of Virginia, Charlottesville, VA, USA
i McGill Center for Studies in Aging, Douglas Hospital, Montreal, Quebec, QC, Canada
j Harvard Medical School Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA
k Washington University School of Medicine, St Louis, Missouri, MO, USA
l Vita-Salute San Raffaele University, Milan, Italy
m Department of Clinical Neurosciences, Cognitive Neurorehabilitation, Milan, Italy
n Dementia Research Centre, Department of Neurodegeneration, Institute of Neurology, University College London, London, UK
o Dementia Research Centre, National Hospital, London, UK
p Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA), Middelheim and Hoge Beuken, Antwerp, Belgium
q Reference Centre for Biological Markers of Dementia, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium
r Hopitaux Universitaires et Université de Genève, Geneva, Switzerland
s IRCCS Fatebenefratelli, Brescia, Italy
t HUG Belle-Idée, bâtiment les Voirons, Chêne-Bourg, France
u Department of Neurosciences, -University of California, San Diego, CA, USA
v INSERM UMR, Paris, France
w AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Médecine Nucléaire, Paris, France
x University of Kentucky Alzheimer's Disease Center, Lexington, KY, USA
y Karolinska Institutet, Karolinska University Hospital Huddinge, Alzheimer Neurobiology Center, Stockholm, Sweden
z Université Lille Nord de France, Lille, France
aa CHRU, Clinique Neurologique, Hôpital Roger Salengro, Lille, France
ab UCSF Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
ac EA CoBTeK and Memory Center, CHU University of Nice, UNSA, Hôpital de Cimiez 4 av Victoria, Nice, France
ad FRACP, Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Melbourne, VIC, Australia
ae Neurology and the Memory and Aging Program, Butler Hospital, Department of Neurology and Psychiatry, The Warren Alpert Medical School of Brown University, Providence, RI, USA
af Neurologie de la Mémoire et du Langage, Centre Hospitalier Sainte-Anne, Paris Cedex, France
ag Université Paris 5, Paris, France
ah Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil
ai Gerontopole, Pavillon Junod, University Toulouse 3, Toulouse, France
aj Department of Psychiatry and Neuropsychology, Alzheimer Centre Limburg, School of Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, Netherlands
ak Department of Neurology and Alzheimer Center, Amsterdam, Netherlands
al Department of Psychiatry, Neurology, and Gerontology, Keck School of Medicine of USC, Los Angeles, CA, USA
am Cognitive Neuroscience Division of the Taub Institute, Presbyterian Hospital, New York, NY, USA
an Alzheimer Centrum Vrije Universiteit Medical Center, VU University, Amsterdam, Netherlands
ao Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, USA
Corresponding Author Information Correspondence to: Prof Bruno Dubois, Centre des Maladies Cognitives et Comportementales, Pavillon F Lhermitte,